Bank of New York Mellon Corp Reduces Stock Position in Bruker Corporation $BRKR

Bank of New York Mellon Corp cut its stake in Bruker Corporation (NASDAQ:BRKR) by 6.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 780,955 shares of the medical research company’s stock after selling 55,379 shares during the period. Bank of New York Mellon Corp’s holdings in Bruker were worth $28,208,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BRKR. Allworth Financial LP grew its holdings in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the period. Federated Hermes Inc. increased its stake in Bruker by 6.7% in the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock valued at $284,000 after purchasing an additional 380 shares in the last quarter. Parallel Advisors LLC raised its holdings in Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares during the last quarter. State of Michigan Retirement System raised its holdings in Bruker by 1.9% during the first quarter. State of Michigan Retirement System now owns 26,693 shares of the medical research company’s stock worth $964,000 after purchasing an additional 500 shares during the last quarter. Finally, CWM LLC boosted its position in Bruker by 49.8% during the fourth quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after purchasing an additional 542 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BRKR. Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. UBS Group set a $60.00 price target on Bruker in a research note on Wednesday, June 24th. Citigroup boosted their price objective on shares of Bruker from $44.00 to $60.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Stifel Nicolaus set a $45.00 price objective on shares of Bruker in a research note on Friday, May 8th. Finally, Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $56.79.

Bruker Stock Performance

NASDAQ:BRKR opened at $60.05 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The firm has a market cap of $9.14 billion, a PE ratio of -250.21, a P/E/G ratio of 1.94 and a beta of 1.29. The firm has a 50 day simple moving average of $56.66 and a 200-day simple moving average of $46.34. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $64.54.

Bruker (NASDAQ:BRKR) last announced its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. Bruker’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were issued a dividend of $0.05 per share. The ex-dividend date was Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s dividend payout ratio (DPR) is -83.33%.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.